Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ERBB2 mutation: A promising target in non-squamous cervical cancer.

Gynecologic oncology - 1 Feb 2018

Xiang Libing, Jiang Wei, Ye Shuang, He Tiancong, Pei Xuan, Li Jiajia, Chan David Wai, Ngan Hextan Yuen Sheung, Li Fang, Tao Pingping, Shen Xuxia, Zhou Xiaoyan, Wu Xiaohua, Yang Gong, Yang Huijuan

Abstract excerpt

OBJECTIVE: ERBB2 mutations have been found in a subset of invasive cervical cancer (ICC). Nevertheless, the prevalence, mutation spectrum, clinicopathological relevance, human papillomavirus (HPV)-genotype association and prognostic significance of ERBB2-mutated ICCs have not been well established. METHODS: In this study, ICC samples (N=1015) were assessed for mutations in ERBB2, KRAS, and PIK3CA by cDNA-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to Molecular Targeted Therapy

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptor, ErbB-2

Share to Uterine Cervical Neoplasms

Source

Identifiers

PMID: 29279289
DOI: 10.1016/j.ygyno.2017.12.023

Genes

ERBB2
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ERBB2 mutation: A promising target in non-squamous cervical cancer.PMID 29279289Read ↗

Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.Semantic proximity Read ↗

Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma.Semantic proximity Read ↗

Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study.Semantic proximity Read ↗

An analysis of HER2 amplification in cervical adenocarcinoma: correlation with clinical outcomes and the International Endocervical Adenocarcinoma Criteria and Classification.Semantic proximity Read ↗

Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers.Semantic proximity Read ↗

Mutational analysis of KRAS and its clinical implications in cervical cancer patients.Semantic proximity Read ↗

Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3.Semantic proximity Read ↗

The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway.Semantic proximity Read ↗

Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma.Semantic proximity Read ↗

ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas.Semantic proximity Read ↗

RB1 alteration and poor prognosis in women with high-grade neuroendocrine carcinoma of the uterine cervix: a NeCTuR study.Semantic proximity Read ↗

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.